T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2851
Unisys
UIS
$210M
| $158K | ﹤0.01% |
57,187
| – | – |
|
2852
DiaMedica Therapeutics
DMAC
$362M
| $157K | ﹤0.01% |
19,660
| – | – |
|
|
KWY
2853
Kingsway Corp
KWY
$283M
| $157K | ﹤0.01% |
11,625
| – | – |
|
2854
JELD-WEN Holding
JELD
$170M
| $156K | ﹤0.01% |
63,171
-18,500
| -23% | -$60.8K |
|
2855
OppFi
OPFI
$607M
| $156K | ﹤0.01% |
14,889
+2,741
| +23% | +$27.8K |
|
2856
Puma Biotechnology
PBYI
$451M
| $155K | ﹤0.01% |
25,936
+4,311
| +20% | +$22.9K |
|
2857
Pulse Biosciences
PLSE
$3.21B
| $155K | ﹤0.01% |
11,231
+330
| +3% | +$5.14K |
|
2858
Ranger Energy Services
RNGR
$401M
| $155K | ﹤0.01% |
11,085
| – | – |
|
2859
SkinHealth Systems
SKIN
$85.4M
| $154K | ﹤0.01% |
110,711
| – | – |
|
2860
Latham Group
SWIM
$896M
| $153K | ﹤0.01% |
23,957
| – | – |
|
2861
Repay Holdings
RPAY
$310M
| $152K | ﹤0.01% |
41,456
| – | – |
|
|
BLFY
2862
DELISTED
Blue Foundry Bancorp
BLFY
| $151K | ﹤0.01% |
+12,102
| New | +$121K |
|
2863
Backblaze
BLZE
$1.27B
| $151K | ﹤0.01% |
32,219
+3,523
| +12% | +$24.1K |
|
2864
Inspired Entertainment
INSE
$166M
| $151K | ﹤0.01% |
16,085
+3,571
| +29% | +$30.1K |
|
2865
National CineMedia
NCMI
$245M
| $151K | ﹤0.01% |
38,712
+5,390
| +16% | +$22.3K |
|
|
PAL
2866
Proficient Auto Logistics
PAL
$154M
| $151K | ﹤0.01% |
15,636
+3,810
| +32% | +$29.9K |
|
2867
Design Therapeutics
DSGN
$907M
| $148K | ﹤0.01% |
15,711
-603
| -4% | -$4.72K |
|
2868
Safe Bulkers
SB
$781M
| $148K | ﹤0.01% |
30,629
| – | – |
|
|
FIRY
2869
Firy Inc
FIRY
$157M
| $148K | ﹤0.01% |
34,215
| – | – |
|
2870
Xponential Fitness
XPOF
$210M
| $148K | ﹤0.01% |
17,958
+3,999
| +29% | +$28.4K |
|
|
CIO
2871
DELISTED
City Office REIT
CIO
| $147K | ﹤0.01% |
20,966
| – | – |
|
2872
Kelly Services Class A
KELYA
$557M
| $147K | ﹤0.01% |
16,688
+615
| +4% | +$6.25K |
|
2873
El Pollo Loco
LOCO
$467M
| $147K | ﹤0.01% |
14,019
| – | – |
|
2874
Candel Therapeutics
CADL
$835M
| $146K | ﹤0.01% |
25,814
+6,176
| +31% | +$33.2K |
|
|
KLC
2875
KinderCare Learning Companies
KLC
$576M
| $146K | ﹤0.01% |
33,603
+17,800
| +113% | +$89.7K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.